Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Core Insights - Revive Therapeutics Ltd. has achieved significant intellectual property milestones for its bucillamine franchise, focusing on applications in medical countermeasures and infectious diseases [1] Group 1: Intellectual Property Developments - The company has filed U.S. and Canadian national phase patent applications under PCT/CA2024/000008 for the use of bucillamine in treating victims exposed to chemical warfare agents [1] - Revive has also been granted Canadian Patent No. for its bucillamine formulations, enhancing its competitive position in the market [1]